vTv Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-12.9%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$2.10next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| CATT1 Phase 3 Topline Data Readout | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
CATT1 Phase 3 Trial Enrollment Completion QuarterlyTarget: Complete enrollment in Q3 2026
Cash and Cash Equivalents Quarterly98.1MTarget: Sufficient to fund operations past CATT1 topline readout
Quarterly R&D Expense Quarterly9MTarget: Reflects ongoing investment in Phase 3 CATT1 trial
Watch Items
- CATT1 Phase 3 Topline Data ReadoutTrigger: Topline data release expected in 2H 2026Action: Evaluate clinical efficacy (HbA1c reduction, hypoglycemia rates) and safety profile to prepare for potential NDA submission.
- Newsoara PDE4 Inhibitor (HPP737) Development MilestonesTrigger: Up to $50.0 million in development milestonesAction: Monitor partner progress to recognize non-dilutive milestone revenues.
Research as of 19 Jun 2026